Running Point Capital Advisors, LLC Clovis Oncology, Inc. Transaction History

Running Point Capital Advisors, LLC

  • $256 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022
BUY
$1.43 - $3.14 $14,300 - $31,400
10,000 New
10,000 $20,000

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0
View Full List

About Clovis Oncology, Inc.

CLVS Quotes by TradingView
  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Running Point Capital Advisors, LLC Portfolio

Follow Running Point Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Running Point Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Running Point Capital Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email